

MMWRTM
**MORBIDITY AND MORTALITY
WEEKLY REPORT**

- 1 Neural Tube Defect Surveillance and Folic Acid Intervention — Texas-Mexico Border, 1993–1998
- 4 HIV/AIDS Among Racial/Ethnic Minority Men Who Have Sex with Men — United States, 1989–1998
- 11 Hypothermia-Related Deaths — Alaska, October 1998–April 1999, and Trends in the United States, 1979–1996

**Neural Tube Defect Surveillance and Folic Acid Intervention —
Texas-Mexico Border, 1993–1998**

Neural tube defects (NTDs) are common and serious malformations that originate early in pregnancy. In the United States, approximately 4000 pregnancies each year are affected by the two most common NTDs (spina bifida and anencephaly). In 1992, the Texas Department of Health (TDH), with support from a CDC cooperative agreement, implemented the Texas Neural Tube Defect Project (TNTDP), a program of NTD surveillance and risk-reduction activities in the 14 counties that border Mexico. The project was initiated in response to an anencephaly cluster identified during 1990–1991 in Brownsville (Cameron County), Texas (1). Whether the high anencephaly rate (19.7 per 10,000 live births) was unique to Cameron County or was characteristic of the entire border was unknown. This report summarizes NTD surveillance rates for the 14 Texas-Mexico border counties for 1993–1998 and presents preliminary results of TNTDP efforts to prevent the recurrence of NTDs by providing folic acid to high-risk women. Findings indicate that the baseline rate along the border is high (13.4 per 10,000 live births) and largely reflects the rate among Hispanics (13.8). Although a longer period is needed to obtain definitive results, folic acid appears to be effective for reducing the risk for NTD recurrence in Hispanics.

The TNTDP surveillance system involved prospective case finding (*International Classification of Diseases, Ninth Revision* [ICD-9], codes 740, 741, and 742.0, for all gestational ages) using the following data sources: hospitals; birthing centers; ultrasound centers; abortion centers; prenatal clinics; genetics clinics; and birth attendants including lay midwives, certified nurse midwives, and nonhospital physicians. Data on NTD cases were collected by three field teams (El Paso, Harlingen, and Laredo), abstracted onto standardized forms, and sent to TDH with confirmatory medical records. Denominator data (live birth, death, and fetal death records) were derived from the Bureau of Vital Statistics at TDH; 91% of the resident live births in the border counties were to Hispanic women of Mexican ancestry.

For 1993–1998, NTD surveillance rates include cases at all gestational ages for the 14 Texas-Mexico border counties (Table 1). The surveillance system identified 360 resident NTD-affected births/terminations (cases) not otherwise accompanied by a known trisomy, triploidy, or syndrome (e.g., Turner, Meckel, or amniotic band). Of these cases, 324 (90%) occurred in the four most populous border counties—Cameron, El Paso, Hidalgo, and Webb. The overall NTD rate in the border counties for 1993–1998

*Neural Tube Defects — Continued***TABLE 1. Neural tube defect (NTD) type* and rate,† by county of residence — Texas-Mexico border, 1993–1998**

County	Anencephaly [§]		Spina bifida		All NTDs		
	No. cases	Rate	No. cases	Rate	Total [¶]	Rate	(95% CI ^{**})
Cameron	31	6.7	38	8.2	73	15.8	(12.4–19.8)
El Paso	39	4.3	36	4.0	82	9.0	(7.2–11.2)
Hidalgo	48	6.2	60	7.7	118	15.1	(12.5–18.1)
Webb	28	9.3	19	6.3	51	16.9	(12.6–22.2)
Other 10	17	7.1	17	7.1	36	14.9	(10.5–20.7)
Total	163	6.1	170	6.3	360	13.4	(12.0–14.8)

*NTD cases exclude the following accompanying conditions: trisomy (three), triploidy (three), Turner (one), Meckel (three), tethered cord (three), and amniotic band syndrome (four).

†Per 10,000 live-born infants.

§Includes craniorachischisis (13) and inencephaly (one).

¶Total includes encephaloceles (27).

** Confidence interval.

was 13.4 per 10,000 live births (6.1 for anencephaly, 6.3 for spina bifida, and 1.0 for encephalocele) (Table 1). The craniorachischisis (contiguous opening of brain and spinal column; included in anencephaly) rate in the border counties was 0.5.

Of the 360 women identified as having had an NTD-affected pregnancy, 340 (94.4%) were Hispanic. Of the 20 non-Hispanic women, 16 (4.4%) were white, three (0.8%) were black, and one (0.3%) was Asian/Pacific Islander. The rate among Hispanics was 13.8 per 10,000 live births and the rate among non-Hispanic whites was 8.8 ($p=0.08$). El Paso County (the northwesternmost county) had a significantly lower NTD rate (9.0) than the rest of the border counties combined (15.6; $p<0.001$). The rate among Hispanics also was significantly lower for El Paso County (8.8) than that for the rest of the border counties (16.1) ($p<0.001$).

Of the NTD-affected pregnancies, 68 (19%) were induced or spontaneously aborted at <20 weeks' gestation, 94 (26%) were delivered or induced at 20 through 33 weeks' gestation, and 198 (55%) were delivered at ≥ 34 weeks' gestation. Excluding fetuses that failed to reach 20 weeks' gestation would have lowered the overall rate to 10.8 per 10,000 live births ($p=0.01$).

The primary objective of TNTDP is preventing recurrence of NTDs by providing folic acid to women who have had an NTD-affected pregnancy. For the folic acid intervention program, all women identified through the surveillance protocol were contacted by telephone, letter, and/or in person. Women whose index pregnancy was delivered or terminated in 1993 or later and who resided in the study area were asked to enroll in the program. The enrolled women were interviewed and provided preconception, pregnancy, and NTD risk-reduction education and counseling. If the women used contraception, they were given a multivitamin with 0.4 mg folic acid; if the women did not use contraception, they were given daily doses consisting of 4.0 mg folic acid—one multivitamin containing 1.0 mg of folic acid and three 1.0 mg tablets of folic acid. Women were followed, counseled, and provided folic acid supplements at 1- to 3-month intervals.

As of December 31, 1998, 264 (73%) of the 360 women were eligible for enrollment in the folic acid intervention program; 96 (27%) women were not eligible for

Neural Tube Defects — Continued

enrollment (moved out of area or had tubal ligations/hysterectomies). Of the 264 eligible women, 95 (36%) refused enrollment, quit, or were lost to follow-up; 17 (6%) consented but were pending enrollment; and 152 (58%) were taking folic acid. Of 65 (34%) eligible women with induced abortions, 22 (34%) refused participation in the folic acid intervention compared with 19 (15%) of 128 ($p=0.004$) who had had natural outcomes (i.e., live-born infants, stillbirths, or spontaneous abortions).

Pregnancy outcomes following the index NTD-affected pregnancy were assessed by telephone, letter, and home visits for 1993–1998. Overall, 89% of the women who had a subsequent pregnancy had taken folic acid before conception; of these, 64% had taken the daily 4.0 mg dose; 28%, the 0.4 mg dose; and 8%, a physician-prescribed prenatal vitamin. A pregnancy outcome was documented for 148 pregnancies; 117 (79%) of the pregnancies resulted in non-NTD-affected live births, 24 (16%) in miscarriages or incomplete spontaneous abortions, six (4%) in elective abortions, and one (1%) in a confirmed recurrent NTD. Five women known to be pregnant were lost to follow-up. None of the six elective abortions was NTD-affected. Excluding the 24 miscarriages and five pregnancies lost to follow-up, one of the remaining 124 pregnancies resulted in a recurrent NTD.

Reported by: K Hendricks, MD, R Larsen, PhD, L Suarez, PhD, Texas Neural Tube Defect Project, Texas Dept of Health. Birth Defects and Pediatric Genetics Br, Div of Birth Defects, Child Development, Disability, and Health (proposed), National Center for Environmental Health, CDC.

Editorial Note: The preliminary results of the folic acid intervention suggest that high-risk women can reduce their risk for subsequent NTD-affected pregnancies. Each woman identified through the TNTDP surveillance protocol was at risk for recurrence and could not have been enrolled in the folic acid intervention program without being identified through surveillance. One fifth of the high-risk women in the program would have been missed if only fetuses at >20 weeks' gestation were included in the surveillance. Why women with induced abortions are less likely to take folic acid than women with natural outcomes is unclear and warrants further study. The woman who had a recurrent NTD-affected baby refused to meet with field staff and never received NTD risk-reduction education, counseling, or folic acid. The one NTD recurrence was less than the three to five that would have been expected based on a 3% to 4% recurrence rate ($p=0.18$, 0.10 respectively).

The NTD surveillance data indicate that baseline rates along the border are high and largely reflect the rate among Hispanics. Some of the variability in the rates may be partially explained by the unique cultural and environmental factors along the border. For example, compared with the rest of the border, El Paso County residents have a higher standard of living and are less likely to be employed as migrant farm workers (1). In addition, the overall Texas-Mexico border rate for craniorachischisis was 0.5, a rate significantly higher ($p=0.048$) than the rate for this defect in the metropolitan Atlanta area (0.1) (2). This suggests that an unknown risk factor may exist, especially in Hidalgo County where six (46%) of these rare defects occurred. Findings from the 1993–1998 recurrence period showed that only 9% of El Paso County women who delivered normal live-born infants reported taking periconceptional folic acid (TNTDP, unpublished data, 1999). Although the 9% usage reported for El Paso County is low compared with national reported usage (25%) (3), usage for Cameron County is even lower (3%).

Neural Tube Defects — Continued

The findings in this report are subject to at least two limitations. First, nonresident women who migrated for birth into the United States and either returned to Mexico or to another county were not eligible for the intervention program; further, resident women who moved, were lost to followup, or had tubal ligations/hysterectomies decreased the potential intervention sample size by 40%. Second, some underestimate of cases occurred because of pregnancy outcomes that occurred outside the area.

Although a sufficient number of pregnancy outcomes have yet to occur among high-risk women to achieve statistical significance, folic acid appears to reduce the risk for NTD recurrence in Hispanic women. Unlike other U.S. surveillance systems (4,5), since its inception the TNTDP has included cases at <20 weeks' gestational age. These data underscore the importance of a timely and active NTD surveillance system that includes fetuses at <20 weeks' gestational age for population-based and individual NTD prevention. They also highlight the need for physicians to educate their high- and low-risk patients about the benefits of folic acid (6,7).

References

1. Hendricks KA, Simpson JS, Larsen RD. Neural tube defects along the Texas-Mexico border, 1993–1995. *Am J Epidemiol* 1999;149:1119–27.
2. Moore CA, Li S, Li Z, et al. Elevated rates of severe neural tube defects in a high prevalence area in Northern China. *Am J Med Genet* 1997;73:113–8.
3. CDC. Knowledge and use of folic acid by women of childbearing age—United States, 1995. *MMWR* 1995;44:716–8.
4. Roberts HE, Moore CA, Cragen JD, et al. Impact of prenatal diagnosis on the birth prevalence of neural tube defects, Atlanta, 1990–1991. *Pediatrics* 1995;96:880–3.
5. Velie EM, Shaw GM. Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989–1991. *Am J Epidemiol* 1996;144:473–9.
6. Smithells RW, Seller MJ, Nevin NC, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. *Lancet* 1983;1:1027–31.
7. American Academy of Pediatrics, Committee on Genetics. Folic acid for the prevention of neural tube defects. *Pediatrics* 1999;104:325–7.

HIV/AIDS Among Racial/Ethnic Minority Men Who Have Sex with Men — United States, 1989–1998

In the United States, racial/ethnic minority populations account for an increasing proportion of acquired immunodeficiency syndrome (AIDS) cases, including cases among men who have sex with men (MSM) (1). This report presents recent trends in AIDS incidence and deaths among MSM who belong to racial/ethnic minority populations*, and compares data on human immunodeficiency virus (HIV) diagnoses with AIDS diagnoses during 1996–1998 among racial/ethnic minority MSM in the 25 states† that have conducted confidential HIV surveillance and AIDS case surveillance since 1994. The findings indicate that among MSM, non-Hispanic black and Hispanic men accounted for an increasing proportion of AIDS cases and had smaller proportionate declines in AIDS incidence and deaths from 1996 to 1998. Of HIV and AIDS diagnoses

*Non-Hispanic black, Hispanic, American Indian/Alaska Native, and Asian/Pacific Islander men aged ≥13 years who have sex with men.

†Alabama, Arizona, Arkansas, Colorado, Idaho, Indiana, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Utah, Virginia, West Virginia, Wisconsin, and Wyoming.

HIV/AIDS — Continued

among racial/ethnic minority MSM, the proportion who are young (aged 13–24 years) is higher than among white MSM.

Trends in AIDS incidence during 1989–1998 among MSM aged ≥ 13 years from the 50 states, the District of Columbia, and U.S. territories were analyzed by race/ethnicity, age, and geographic area of residence. During 1996–1998, AIDS incidence per 100,000 population was calculated using race/ethnicity-specific Bureau of the Census estimates of males aged ≥ 13 years for the corresponding years. The number of HIV infection and AIDS diagnoses and deaths among persons with AIDS was adjusted for reporting delays on the basis of cases reported to CDC through June 30, 1999, and for the anticipated reclassification of cases initially reported without HIV-infection risk-exposure data (1). Trends examined were from 1989 through 1998 and from 1996 through 1998, the period of highly active antiretroviral therapy (HAART). During 1996–1998, for the 25 states with confidential HIV surveillance, age and race/ethnicity of MSM whose disease status was HIV infection (not AIDS) when initially diagnosed were compared with MSM who had AIDS-defining conditions when first diagnosed.

Characteristics of MSM with AIDS

During 1996–1998, 64,685 MSM were diagnosed with AIDS (Table 1); 31,866 (49%) were racial/ethnic minority MSM. Among this group, 1,492 (5%) were aged 13–24 years and 4,498 (14%) were aged 25–29 years, compared with 2% and 9%, respectively, of white MSM in those age categories. Metropolitan statistical areas (MSAs) of $\geq 500,000$ population accounted for 27,097 (85%) AIDS cases in racial/ethnic minority MSM. The AIDS incidence in MSM per 100,000 adult male population decreased 32% from 1996 to 1998 (Table 1); rates were highest for black MSM in all years.

The five MSAs that accounted for the largest number of racial/ethnic minority MSM with AIDS during 1996–1998 were New York, 3,673 (12%); Los Angeles, 2,811 (9%); Miami, 1,554 (5%); Washington, DC, 1,251 (4%); and Chicago, 1,075 (3%). New York and Los Angeles had the largest number of AIDS cases among non-Hispanic black and Hispanic MSM, respectively. Los Angeles and Phoenix were the MSAs with the largest number of AIDS cases among Asian/Pacific Islander (A/PI) and American Indian/Alaska Native (AI/AN) MSM, respectively, compared with New York for white MSM (Table 2).

Trends in AIDS Incidence and Deaths Among MSM with AIDS

During 1989–1998, AIDS was diagnosed in 290,582 MSM. In 1989, racial/ethnic minority MSM accounted for 24,444 (31%) AIDS cases among MSM, and by 1998, racial/ethnic minority MSM accounted for 18,153 (52%) AIDS cases among MSM (Figure 1). The proportion of MSM with AIDS who were non-Hispanic black and Hispanic increased from 19% and 12%, respectively, in 1989, to 33% and 18%, respectively, in 1998. A/PI and AI/AN each accounted for $<2\%$ of AIDS cases among MSM throughout this period.

AIDS incidence among all MSM declined 22% from 1996 to 1997 (Table 1). The rate of decline slowed to 12% in 1998 compared with 1997. During 1996–1998, AIDS incidence declined among MSM in all racial/ethnic groups: A/PI (43%), non-Hispanic white (39%), AI/AN (35%), Hispanic (26%), and non-Hispanic black (23%). Overall, the proportionate declines in AIDS incidence from 1997 to 1998 were smaller than those from 1996 to 1997. From 1997 to 1998, AIDS incidence declined 29% among AI/AN, 17% among A/PI, 15% among non-Hispanic white, 10% among non-Hispanic black, and 9% among Hispanic MSM.

TABLE 1. Number and rate of AIDS cases and deaths from AIDS among men aged ≥ 13 years who have sex with men, and estimated number and percentage in whom AIDS was diagnosed, by race/ethnicity, age at diagnosis, geographic region, and size of metropolitan statistical area (MSA) — United States, 1996–1998

Characteristic	White, non-Hispanic		Black, non-Hispanic		Hispanic		Asian/ Pacific Islander		American Indian/ Alaska Native		Total*
No. cases[†]											
1996	13,903		7,534		4,197		311		81		26,068
1997	10,098		6,491		3,523		225		75		20,464
1998	8,678		5,958		3,224		192		55		18,153
AIDS rate[§]											
1996	17.9		66.2		39.3		9.1		11.3		25.0
1997	12.9		56.2		31.8		6.3		10.4		19.5
1998	11.0		50.7		29.0		5.2		7.4		17.1
No. deaths[¶]											
1996	9,423		4,495		2,271		181		56		16,436
1997	4,381		2,718		1,171		91		34		8,401
1998	3,332		2,135		917		57		21		6,467
	<u>No.</u>	<u>(%)</u>	<u>No.</u>	<u>(%)</u>	<u>No.</u>	<u>(%)</u>	<u>No.</u>	<u>(%)</u>	<u>No.</u>	<u>(%)</u>	
Age (yrs) at AIDS diagnosis											
13–24	526	(2)	933	(5)	521	(5)	31	(4)	7	(4)	2,019
25–29	2,994	(9)	2,710	(13)	1,674	(15)	86	(12)	28	(13)	7,510
30–39	15,323	(47)	9,417	(47)	5,180	(47)	314	(43)	113	(53)	30,411
40–49	9,460	(29)	4,769	(24)	2,446	(23)	215	(30)	46	(22)	16,975
≥ 50	4,376	(13)	2,154	(11)	1,123	(10)	82	(11)	17	(8)	7,770
Region** and MSA size^{††}											
Northeast											
$\geq 500,000$	4,875	(15)	3,815	(19)	2,191	(20)	104	(14)	5	(2)	11,084
$< 500,000$	657	(2)	226	(1)	110	(1)	3	(<1)	0	(0)	1,006
North Central											
$\geq 500,000$	3,136	(9)	2,485	(12)	323	(3)	31	(4)	15	(7)	5,992
$< 500,000$	1,347	(4)	268	(1)	83	(<1)	2	(<1)	10	(5)	1,710

South											
≥500,000	9,142	(28)	8,016	(40)	2,826	(26)	73	(10)	33	(16)	20,097
<500,000	3,253	(11)	2,561	(13)	392	(4)	12	(2)	20	(9)	6,242
West											
≥500,000	8,844	(27)	2,269	(11)	3,807	(35)	453	(62)	83	(39)	15,471
<500,000	1,282	(4)	146	(1)	311	(3)	42	(6)	45	(21)	1,830
Territories											
≥500,000	2	(<1)	0	(0)	568	(5)	0	(0)	0	(0)	570
<500,000	6	(<1)	16	(<1)	291	(2)	4	(1)	0	(0)	317

* Estimates are adjusted for delays in reporting of AIDS cases and anticipated redistribution of cases initially reported with no identified risk; data reported to CDC through June 1999.

† Row totals include men for whom race/ethnicity was unknown or missing; column totals may include men for whom information was missing for some categories.

§ Per 100,000 males aged ≥13 years.

¶ Estimates are adjusted for delays in reporting of deaths and anticipated redistribution of cases initially reported with no identified risk; data reported to CDC through June 1999.

** *Northeast*=Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; *North Central*=Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; *South*=Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; *West*=Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

†† Areas with <500,000 population include areas not in MSAs.

HIV/AIDS — Continued

TABLE 2. Metropolitan statistical areas (MSAs)* with the highest number of AIDS cases† among men aged ≥13 years who have sex with men (MSM) — United States, 1996–1998

Race/Ethnicity (No. cases)	MSA	No. cases	% of racial/ethnic total
Black, non-Hispanic (19,983)	New York, N.Y.	2,034	10.2
	Washington, D.C.	1,135	5.7
	Atlanta, Ga.	951	4.8
	Los Angeles-Long Beach, Calif.	947	4.7
	Chicago, Ill.	848	4.2
	Total		5,915
Hispanic (10,944)	Los Angeles-Long Beach, Calif.	1,728	15.8
	New York, N.Y.	1,570	14.3
	Miami, Fla.	879	8.0
	San Juan-Bayamon, Puerto Rico	568	5.2
	San Diego, Calif.	365	3.3
	Total		5,110
Asian/Pacific Islander (728)	Los Angeles-Long Beach, Calif.	126	17.3
	San Francisco, Calif.	84	11.5
	Honolulu, Hawaii	71	9.8
	New York, N.Y.	67	9.2
	San Diego, Calif.	36	5.0
	Total		384
American Indian/Alaska Native (211)	Phoenix-Mesa, Ariz.	18	8.5
	Seattle-Bellevue-Everett, Wash.	11	5.2
	Tulsa, Okla.	10	4.7
	Los Angeles-Long Beach, Calif.	9	4.2
	San Diego, Calif.	7	3.3
	Total		55
White, non-Hispanic (32,679)	New York, N.Y.	2,138	6.5
	Los Angeles-Long Beach, Calif.	1,931	5.9
	San Francisco, Calif.	1,456	4.5
	Houston, Texas	1,003	3.1
	Dallas, Texas	902	2.8
	Total		7,430


*Includes only metropolitan areas with a population ≥500,000. Metropolitan areas are named for a central city or county, may include several cities and counties, and may cross state boundaries.

†Estimates are adjusted for delays in reporting of AIDS cases and anticipated redistribution of cases initially reported with no identified risk; data reported to CDC through June 1999.

§29.6% of 19,983 AIDS cases among non-Hispanic black MSM resided in these five MSAs.

Deaths among all MSM with AIDS declined 49% from 1996 to 1997 (Table 1). The rate of decline slowed to 23% in 1998 compared with 1997. From 1996 to 1998, AIDS deaths declined among all racial/ethnic MSM: A/PI (69%), non-Hispanic white (65%), AI/AN (63%), Hispanic (60%), and non-Hispanic black (53%). From 1997 to 1998, AIDS deaths declined 38% among AI/AN, 37% among A/PI, 24% among non-Hispanic white, 22% among Hispanic, and 21% among non-Hispanic black MSM.

HIV/AIDS — Continued

FIGURE 1. Proportion of AIDS cases* among men aged ≥ 13 years who have sex with men (MSM), by race/ethnicity and year of diagnosis — United States, 1989–1998

*Estimated number of AIDS diagnoses adjusted for delays in reporting of AIDS cases and anticipated redistribution of cases initially reported with no identified risk; data reported to CDC through June 1999.

†Defined as non-Hispanic black, Hispanic, American Indian/Alaska Native, and Asian/Pacific Islander MSM.

HIV and AIDS Diagnoses Among MSM in 25 Areas with HIV/AIDS Surveillance

During 1996–1998, HIV infection or AIDS was diagnosed in 23,680 MSM in 25 states with HIV reporting; 11,313 (48%) were racial/ethnic minority MSM: 9497 (40%) non-Hispanic black, 1551 (7%) Hispanic, 113 (<1%) A/PI, and 152 (<1%) AI/AN. Among MSM whose initial diagnosis was HIV infection, the proportion aged 13–24 years varied by race/ethnicity: 16% non-Hispanic black, 15% A/PI, 15% AI/AN, 13% Hispanic, and 9% non-Hispanic white. Among MSM whose initial diagnosis was AIDS, the proportion aged 13–24 years also varied by race/ethnicity: 6% Hispanic, 6% A/PI, 5% non-Hispanic black, 1% non-Hispanic white, and <1% AI/AN.

Reported by: State and territorial health departments; Div of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention; and an EIS Officer, CDC.

Editorial Note: These HIV/AIDS surveillance data highlight the importance of increased efforts to promote HIV prevention and treatment services in racial/ethnic minority communities, particularly among non-Hispanic black and Hispanic MSM.

HIV/AIDS — Continued

These groups had higher AIDS rates and the smallest proportionate decreases in AIDS incidence. The annual number of AIDS cases remains high, although AIDS incidence and deaths have declined among racial/ethnic minority MSM. These declines reflect the beneficial impact of HIV prevention programs, HAART, and opportunistic infection prophylaxis. Young non-Hispanic black and Hispanic MSM remain at high risk for HIV infection as indicated by higher proportions of AIDS and HIV cases among non-Hispanic black and Hispanic MSM aged 13–24 years compared with white MSM.

The disproportionate impact of HIV/AIDS on racial/ethnic minority MSM indicated in this report is probably a minimum estimate. The use of all men aged ≥ 13 years as a denominator (instead of MSM) results in an underestimate of the rate among MSM. Small numbers of cases among A/PI and AI/AN MSM limit the ability to assess trends, although in some locations A/PI and AI/AN MSM might be at substantial risk. HIV/AIDS surveillance data also may underestimate cases among racial/ethnic minorities because of misclassified race/ethnicity in medical records (2), which is greatest among AI/AN, A/PI, and Hispanic groups. States that conduct HIV reporting are not representative of the geographic regions with large Hispanic populations. Race/ethnicity itself is not a risk factor for HIV infection; however, among racial/ethnic minority MSM, social and economic factors, such as homophobia (3), high rates of poverty and unemployment, and lack of access to health care, are associated with high rates of HIV risk behavior (4). These factors also may be barriers to receiving HIV prevention information or accessing HIV testing, diagnosis, and treatment.

Characteristics of persons in whom HIV infection (without AIDS) is diagnosed reflect more recent trends in the epidemic than do characteristics of persons with AIDS. In states with confidential HIV surveillance, a larger proportion of racial/ethnic minority MSM were young (aged 13–24 years) when first diagnosed with HIV infection (without AIDS) compared with white MSM, suggesting that racial/ethnic minority MSM may become infected at younger ages compared with white MSM. Trends in AIDS incidence and deaths are affected now by HIV incidence and by HAART; pre-HAART diagnoses of AIDS were not as substantially affected by treatment. HIV case reports may reflect targeted testing patterns in at-risk populations or differences in test-seeking behavior. However, the increased proportion of racial/ethnic minority MSM among MSM with AIDS and the trends in HIV infection diagnoses, particularly among non-Hispanic black men, are consistent with data from seroprevalence and incidence studies among MSM (5,6), which document the high risk for HIV infection among young racial/ethnic minority MSM. Together with AIDS data, HIV data highlight the extent of the need for prevention and treatment to reduce HIV-related morbidity and mortality in this population.

To reduce infection rates and improve the likelihood of survival, prevention programs for racial/ethnic minority MSM need to focus on both HIV-infected and uninfected populations. Challenges to the design and implementation of HIV prevention programs among racial/ethnic minority MSM include reaching MSM who may not identify themselves as homosexual or bisexual, recognizing the importance of representing racial/ethnic minority MSM in HIV prevention planning, addressing language barriers, and improving access to HIV testing and health care. Within racial/ethnic minority communities, the stigma attached to acknowledging homosexual and bisexual activity may inhibit racial/ethnic minority MSM from identifying themselves as homosexual or bisexual (7), and they may be more likely to identify with their

HIV/AIDS — Continued

racial/ethnic minority community than with the MSM community (8). In a CDC-sponsored study of 8780 MSM with HIV infection or AIDS, 24% of non-Hispanic black MSM, 15% of Hispanic MSM, and 11% of A/PI MSM identified themselves as heterosexual compared with 7% of AI/AN and 6% of non-Hispanic white MSM (CDC, unpublished data, 1999). Racial/ethnic minority community leaders should promote dialogue about issues of sexual orientation to overcome social barriers to HIV prevention for racial/ethnic minority MSM (3), especially among young men.

MSM remain a population at high risk for HIV infection, and continued efforts to promote behavioral risk reduction among at-risk youth are needed. Serologic surveys, HIV/AIDS case surveillance, and supplemental research and evaluation studies of racial/ethnic minority MSM and other HIV-infected and at-risk populations are needed to target intervention programs (9). In 1999, CDC funded a special program to enhance HIV prevention services for racial/ethnic minority MSM (10). CDC and other federal agencies are collaborating to facilitate links between prevention and treatment services for infected and at-risk populations.

References

1. CDC. HIV/AIDS surveillance report. Atlanta, Georgia: US Department of Health and Human Services, CDC, 1999;11(1).
2. Kelly JJ, Chu SY, Diaz T, et al. Race/ethnicity misclassification of persons reported with AIDS. *Ethnicity and Health* 1996;1:87-94.
3. Stokes JP, Peterson JL. Homophobia, self-esteem, and risk for HIV among African-American men who have sex with men. *AIDS Educ Prev* 1998;10:278-92.
4. National Commission on AIDS. *The challenge of HIV/AIDS in communities of color*. Washington, DC: National Commission on AIDS, December 1992.
5. CDC. National HIV prevalence surveys, 1997 summary. Atlanta, Georgia: US Department of Health and Human Services, CDC, 1998.
6. Valleroy L, MacKellar DA, Rosen D, Secura G. HIV and predictors of unprotected receptive anal intercourse for 15-to-22-year old African American men who have sex with men in seven cities, USA. Presented at the 12th World AIDS Conference, Geneva, Switzerland, June 30, 1998.
7. Doll LS, Beeker C. Male bisexual behavior and HIV risk in the United States: synthesis of research with implications for behavioral interventions. *AIDS Educ Prev* 1996;8:205-25.
8. Health Resources and Services Administration. *HIV/AIDS Work Group on Health Care Access Issues for Gay and Bisexual Men of Color*. Washington, DC: US Department of Health and Human Services, 1995:33.
9. CDC. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. *MMWR* 1999;48(no. RR-13).
10. CDC. Community-based HIV prevention services and capacity-building assistance to organizations serving gay men of color at risk for HIV infection; notice of availability of funds. *Federal Register* 1999;64:33293-305.

Hypothermia-Related Deaths — Alaska, October 1998–April 1999, and Trends in the United States, 1979–1996

Hypothermia is defined as an unintentional lowering of the core body temperature to ≤ 95 F (≤ 35 C) (1). It is a medical emergency with a high fatality rate (2). In the United States, hypothermia-related deaths can occur anywhere, including in states with milder climates (e.g., Georgia and North Carolina) where weather systems can cause rapid changes in temperature. However, the highest hypothermia-related death rates

Hypothermia-Related Deaths — Continued

in the United States occur in northern states, where winter is characterized by moderate to severe cold temperatures (e.g., Alaska and Montana), and western states, where profound declines in nighttime temperatures may occur at high elevations (e.g., New Mexico). From October 1998 through April 1999, 16 deaths attributed to hypothermia (*International Classification of Diseases, Ninth Revision* [ICD-9], codes E901.0, E901.8, and E901.9; excludes man-made cold [E901.1]*) were reported to the Alaska State Medical Examiner. This report describes selected cases of hypothermia-related deaths in Alaska during October 1998–April 1999; compares age-, sex-, and race-specific rates in Alaska and the rest of the United States during 1979–1996; and summarizes trends for hypothermia-related deaths in the United States during 1979–1996.

Case Reports

Case 1. In February 1999, a 36-year-old man with a history of binge drinking was found dead between parked cars in the parking area of the local airport. He was last seen alive 18 hours earlier in an extremely intoxicated condition. External examination indicated no evidence of injury or violence except for superficial abrasions on the hands consistent with scraping around in the ice and snow at temperatures of –20 F to –25 F (–29 C to –32 C). The man's postmortem blood alcohol level was 100 mg/dL (the legal blood alcohol limit in Alaska is 100 mg/dL), and his urine alcohol level was 272 mg/dL. An autopsy was not conducted.

Case 2. In January 1999, a 36-year-old man from a northern Alaska village was reported missing after he did not return from a hunting trip. Weather conditions were clear and calm with a temperature of approximately –15 F (–26 C) when he left his village; however, late in the afternoon, 40 mph winds lowered chill factors to –80 F (–62 C), and visibility on the tundra decreased to <200 yards. The man was discovered frozen 6 days later in a small freshly dug snow cave adjacent to his disabled snowmobile. He was wearing a heavy down jacket, beaver hat, ski pants, and heavy felt-lined boots over his usual clothing. No alcoholic beverages were present among his effects. External examination indicated no substantial injuries and an autopsy was not conducted.

Case 3. In March 1999, a 36-year-old man was found 300 yards from his village residence in rural Alaska approximately 7 hours after having last been seen alive. The body was clad only in a pair of briefs and a shirt. The man suffered from a seizure disorder, and in his postictal state would frequently lose awareness of his surroundings and walk around or outside his residence. He had been taking valproic acid for his condition. Postmortem levels of valproic acid indicated a blood concentration of 53.5 mg/mL (therapeutic range: 50.0–100.0 mg/mL). The unbound valproic acid concentration was 19.6 mg/mL (therapeutic range: 6.0 to 20.0 mg/mL). A blood test was negative for alcohol. Autopsy indicated no evidence of a natural disease process or of substantial trauma.

Summary of Cases and U.S. Trends

Of the 16 persons in Alaska whose deaths were attributed to hypothermia, 12 were men. The median age of decedents was 35 years (range: 15–75 years). During 1979–

*These data were obtained from the compressed mortality file (CMF), maintained by CDC's National Center for Health Statistics, and have been prepared according to the external cause-of-death codes from the ICD-9. The CMF contains information from death certificates filed in the 50 states and the District of Columbia.

Hypothermia-Related Deaths — Continued

1996, the age-adjusted rate for hypothermia-related deaths in Alaska was 10 times higher than in the rest of the United States (3.0 per 100,000 population versus 0.3). Hypothermia-related deaths also were more likely to occur among men (rate ratio: 2.4 versus 2.0), persons aged <65 years (rate ratio: 0.3 versus 0.2), and non-whites and non-blacks[†] (rate ratio: 11.7 versus 2.0) in Alaska than elsewhere in the United States.


During 1979–1996, hypothermia-related death rates in the United States decreased significantly ($p=0.014$). In addition, rates decreased among all age and sex groups (Figure 1). Stratification by race indicated that the recent downward trend in hypothermia is strongest among black males aged ≥ 65 years, a population that has one of the highest hypothermia-related death rates in the United States (1979–1996 rate: 6.7 per 100,000 population).

Reported by: MT Propst, MD, Anchorage; JP Middaugh, MD, State Epidemiologist, Div of Public Health, Alaska Dept of Health. Health Studies Br, Div of Environmental Hazards and Health Effects, National Center for Environmental Health; and an EIS Officer, CDC.

Editorial Note: The findings in this report indicate that hypothermia-related deaths in the United States have decreased significantly. Possible reasons for the decrease include changes in reporting, improved prevention measures, and/or more moderate winters. Increases in winter temperatures will result in fewer winter-related deaths (3).

[†]Data on race in the CMF were collected only for whites, blacks, and other races.

FIGURE 1. Rate* of hypothermia-related deaths, by age and sex — United States, 1979–1996



*Per 100,000 population.

Hypothermia-Related Deaths — Continued

Infants, the elderly, persons who are homeless or mentally ill, and persons with serious medical conditions are particularly at risk for hypothermia (4), especially if they use drugs that can induce vasodilatation and suppress the shivering response (e.g., sedatives, anxiolytics, phenothiazines, and tricyclic antidepressants) (5). Men take more risks than women and are more likely to remain outdoors for long periods (i.e., more men are homeless, hikers, and hunters) (4). Race-specific differences may reflect variations in socioeconomic determinants such as access to protective clothing, shelter, or medical care (6).

In all three cases in this report, staying outdoors was a major contributing risk factor for hypothermia. Traveling during extremely cold periods, especially when conditions produce high winds, requires careful planning, awareness of travel advisories, and knowledge of survival techniques should a person become stranded (4). Specific preventive measures include wearing adequate clothing (particularly headgear), maintaining fluid and caloric intake, avoiding fatigue, refraining from alcohol consumption, ensuring availability of emergency shelter, and avoiding heavy exertion (4).

Hypothermia can occur when even moderately low ambient temperatures (e.g., 60 F [15.5 C]) overcome a person's ability to conserve heat (2). The onset of hypothermia is often insidious, with early manifestations of exposure including shivering, numbness, fatigue, poor coordination, slurred speech, impaired mentation, blueness or puffiness of the skin, and irrationality (6). Early recognition and immediate care can improve the prognosis (7). Even if a person appears dead, cardiopulmonary resuscitation should be provided and continued while the person is being warmed, until the person responds, or medical aid becomes available.

In 1997, Mississippi, Missouri, New Mexico, and Wisconsin established surveillance systems for hypothermia (8). Public education and outreach programs targeting high-risk populations are essential to reduce the risk for hypothermia-related death.

References


1. Kilbourne EM. Cold environments. In: Noji EK, ed. The public health consequences of disasters. New York: Oxford University Press, 1997:270–86.
2. Hector MG. Treatment of accidental hypothermia. *Am Fam Physician* 1992;45:785–92.
3. McMichael AJ, Haines A, Slooff R, Kovats S, eds. Climate change and human health. Geneva, Switzerland: World Health Organization, 1996.
4. CDC. Extreme cold: a prevention guide to promote your personal health and safety. Atlanta, Georgia: US Department of Health and Human Services, CDC, 1996.
5. CDC. Hypothermia-related deaths—Virginia, November 1996–April 1997. *MMWR* 1997;46:1157–9.
6. CDC. Hypothermia—United States. *MMWR* 1983;32:46–8.
7. Danz DF, Pozos RS. Accidental hypothermia. *N Engl J Med* 1994;331:1756–60.
8. CDC. Monitoring environmental disease—United States, 1997. *MMWR* 1998;47:522–5.

Erratum: Vol. 48, No. SS-8

In the report, "Surveillance for Morbidity and Mortality Among Older Adults—United States, 1995–1996" in the *MMWR CDC Surveillance Summaries*, "Surveillance for Selected Public Health Indicators Affecting Older Adults—United States," the first footnote (*) in Table 2 on page 13 should read, "Rate per 1000 population; total

(Continued on page 23)

FIGURE I. Selected notifiable disease reports, comparison of provisional 4-week totals ending January 8, 2000, with historical data — United States



*Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary — provisional cases of selected notifiable diseases, United States, cumulative, week ending January 8, 2000 (1st Week)

	Cum. 2000		Cum. 2000
Anthrax	-	HIV infection, pediatric* ⁵	-
Brucellosis*	-	Plague	-
Cholera	-	Poliomyelitis, paralytic	-
Congenital rubella syndrome	-	Psittacosis*	-
Cyclosporiasis*	-	Rabies, human	-
Diphtheria	-	Rocky Mountain spotted fever (RMSF)	3
Encephalitis: California*	-	Streptococcal disease, invasive Group A	12
eastern equine*	-	Streptococcal toxic-shock syndrome*	2
St. Louis*	-	Syphilis, congenital [¶]	-
western equine*	-	Tetanus	-
Ehrlichiosis	-	Toxic-shock syndrome	-
human granulocytic (HGE)*	-	Trichinosis	-
human monocytic (HME)*	-	Typhoid fever	1
Hansen Disease*	-	Yellow fever	-
Hantavirus pulmonary syndrome* [†] .	-		
Hemolytic uremic syndrome, post-diarrheal*	-		

-:no reported cases

*Not notifiable in all states.

[†] Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID).

⁵ Updated monthly from reports to the Division of HIV/AIDS Prevention—Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP), last update December 26, 1999.

[¶] Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending January 8, 2000, and January 9, 1999 (1st Week)

Reporting Area	AIDS		Chlamydia [§]		Cryptosporidiosis		<i>Escherichia coli</i> O157:H7*			
	Cum. 2000 [†]	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	NETSS		PHLIS	
							Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	-	-	2,477	11,412	1	16	3	19	1	17
NEW ENGLAND	-	-	212	325	-	-	-	3	1	3
Maine	-	-	-	-	-	-	-	-	-	-
N.H.	-	-	11	19	-	-	-	-	1	-
Vt.	-	-	8	6	-	-	-	-	-	-
Mass.	-	-	193	187	-	-	-	3	-	2
R.I.	-	-	-	35	-	-	-	-	-	-
Conn.	-	-	-	78	-	-	-	-	-	1
MID. ATLANTIC	-	-	16	1,415	-	5	-	1	-	-
Upstate N.Y.	-	-	N	N	-	-	-	1	-	-
N.Y. City	-	-	-	838	-	4	-	-	-	-
N.J.	-	-	16	156	-	-	-	-	-	-
Pa.	-	-	-	421	-	1	N	N	-	-
E.N. CENTRAL	-	-	825	1,859	-	4	2	9	-	4
Ohio	-	-	90	767	-	2	1	9	-	2
Ind.	-	-	100	162	-	-	-	-	-	-
Ill.	-	-	351	501	-	1	-	-	-	1
Mich.	-	-	-	175	-	-	1	-	-	-
Wis.	-	-	284	254	-	1	N	N	-	1
W.N. CENTRAL	-	-	92	435	1	1	1	-	-	2
Minn.	-	-	-	161	-	-	-	-	-	2
Iowa	-	-	1	3	-	-	-	-	-	-
Mo.	-	-	67	201	1	1	1	-	-	-
N. Dak.	-	-	-	10	-	-	-	-	-	-
S. Dak.	-	-	24	23	-	-	-	-	-	-
Nebr.	-	-	-	16	-	-	-	-	-	-
Kans.	-	-	-	21	-	-	-	-	-	-
S. ATLANTIC	-	-	583	2,938	-	-	-	3	-	1
Del.	-	-	52	55	-	-	-	-	-	-
Md.	-	-	33	251	-	-	-	1	-	-
D.C.	-	-	-	N	-	-	-	-	U	U
Va.	-	-	176	128	-	-	-	-	-	-
W. Va.	-	-	-	37	-	-	-	-	-	-
N.C.	-	-	322	364	-	-	-	2	-	1
S.C.	-	-	-	958	-	-	-	-	-	-
Ga.	-	-	-	618	-	-	U	U	U	U
Fla.	-	-	-	527	-	-	-	-	-	-
E.S. CENTRAL	-	-	235	556	-	-	-	-	-	-
Ky.	-	-	98	28	-	-	-	-	U	U
Tenn.	-	-	-	92	-	-	-	-	-	-
Ala.	-	-	137	256	-	-	-	-	-	-
Miss.	-	-	-	180	-	-	-	-	-	-
W.S. CENTRAL	-	-	156	1,544	-	-	-	-	-	1
Ark.	-	-	-	54	-	-	-	-	-	1
La.	-	-	-	381	-	-	-	-	-	-
Okla.	-	-	156	140	-	-	-	-	-	-
Tex.	-	-	-	969	-	-	-	-	-	-
MOUNTAIN	-	-	152	584	-	-	-	2	-	3
Mont.	-	-	-	-	-	-	-	-	-	-
Idaho	-	-	-	23	-	-	-	-	-	-
Wyo.	-	-	12	2	-	-	-	-	-	-
Colo.	-	-	68	84	-	-	-	1	-	1
N. Mex.	-	-	-	39	-	-	-	-	-	-
Ariz.	-	-	-	298	-	-	-	-	-	-
Utah	-	-	72	63	N	N	-	1	-	2
Nev.	-	-	-	75	-	-	-	-	-	-
PACIFIC	-	-	206	1,756	-	6	-	1	-	3
Wash.	-	-	188	254	N	N	-	-	-	2
Oreg.	-	-	-	72	-	1	-	1	-	1
Calif.	-	-	-	1,354	-	5	-	-	-	-
Alaska	-	-	18	25	-	-	-	-	-	-
Hawaii	-	-	-	51	-	-	-	-	-	-
Guam	-	-	-	14	-	-	N	N	U	U
P.R.	-	-	-	U	-	-	-	-	U	U
V.I.	-	-	-	U	-	U	-	U	U	U
Amer. Samoa	-	-	-	U	-	U	-	U	U	U
C.N.M.I.	-	-	-	U	-	U	-	U	U	U

N: Not notifiable U: Unavailable -: no reported cases C.N.M.I.: Commonwealth of Northern Mariana Islands

*Individual cases may be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

[†]Updated monthly from reports to the Division of HIV/AIDS Prevention—Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, last update December 26, 1999.

[§]Chlamydia refers to genital infections caused by *C. trachomatis*. Totals reported to the Division of STD Prevention, NCHSTP.

TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States, weeks ending January 8, 2000, and January 9, 1999 (1st Week)

Reporting Area	Gonorrhea		Hepatitis C/NA,NB		Legionellosis		Lyme Disease	
	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	1,525	6,894	6	36	3	10	-	26
NEW ENGLAND	58	130	-	-	-	-	-	6
Maine	-	-	-	-	-	-	-	-
N.H.	1	-	-	-	-	-	-	-
Vt.	-	3	-	-	-	-	-	-
Mass.	57	68	-	-	-	-	-	6
R.I.	-	11	-	-	-	-	-	-
Conn.	-	48	-	-	-	-	-	-
MID. ATLANTIC	12	874	-	-	-	2	-	12
Upstate N.Y.	8	-	-	-	-	-	-	-
N.Y. City	-	493	-	-	-	-	-	3
N.J.	4	145	-	-	-	1	-	6
Pa.	-	236	-	-	-	1	-	3
E.N. CENTRAL	421	1,058	4	19	1	7	-	3
Ohio	51	325	-	-	1	2	-	3
Ind.	52	95	-	-	-	-	-	-
Ill.	168	405	-	1	-	-	-	-
Mich.	-	81	4	18	-	4	-	-
Wis.	150	152	-	-	-	1	U	U
W.N. CENTRAL	41	207	1	3	-	-	-	-
Minn.	3	69	-	-	-	-	-	-
Iowa	4	-	-	-	-	-	-	-
Mo.	31	106	1	3	-	-	-	-
N. Dak.	-	-	-	-	-	-	-	-
S. Dak.	3	2	-	-	-	-	-	-
Nebr.	-	14	-	-	-	-	-	-
Kans.	-	16	-	-	-	-	-	-
S. ATLANTIC	626	2,381	-	3	2	-	-	4
Del.	27	37	-	-	-	-	-	-
Md.	30	384	-	2	1	-	-	4
D.C.	-	86	-	-	-	-	-	-
Va.	212	355	-	-	-	-	-	-
W. Va.	-	16	-	-	N	N	-	-
N.C.	353	348	-	1	1	-	-	-
S.C.	-	363	-	-	-	-	-	-
Ga.	4	334	-	-	-	-	-	-
Fla.	-	458	-	-	-	-	-	-
E.S. CENTRAL	154	574	-	-	-	-	-	-
Ky.	62	32	-	-	-	-	-	-
Tenn.	-	68	-	-	-	-	-	-
Ala.	92	254	-	-	-	-	-	-
Miss.	-	220	-	-	-	-	-	-
W.S. CENTRAL	69	1,143	-	-	-	-	-	-
Ark.	-	60	-	-	-	-	-	-
La.	-	350	-	-	-	-	-	-
Okla.	69	86	-	-	-	-	-	-
Tex.	-	647	-	-	-	-	-	-
MOUNTAIN	111	216	1	5	-	-	-	-
Mont.	-	-	-	-	-	-	-	-
Idaho	-	2	-	1	-	-	-	-
Wyo.	1	1	1	2	-	-	-	-
Colo.	102	45	-	1	-	-	-	-
N. Mex.	-	10	-	1	-	-	-	-
Ariz.	-	122	-	-	-	-	-	-
Utah	8	7	-	-	-	-	-	-
Nev.	-	29	-	-	-	-	-	-
PACIFIC	33	311	-	6	-	1	-	1
Wash.	31	43	-	-	-	-	-	-
Oreg.	-	9	-	-	N	N	-	-
Calif.	-	248	-	6	-	1	-	1
Alaska	2	3	-	-	-	-	-	-
Hawaii	-	8	-	-	-	-	N	N
Guam	-	1	-	-	-	-	-	-
P.R.	-	-	-	-	-	-	N	N
V.I.	-	U	-	U	-	U	-	U
Amer. Samoa	-	U	-	U	-	U	-	U
C.N.M.I.	-	U	-	U	-	U	-	U

N: Not notifiable

U: Unavailable

-: no reported cases

TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States, weeks ending January 8, 2000, and January 9, 1999 (1st Week)

Reporting Area	Malaria		Rabies, Animal		Salmonellosis*			
	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	NETSS		PHLIS	
					Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	3	19	30	60	91	301	5	558
NEW ENGLAND	-	1	1	15	-	27	-	33
Maine	-	-	-	1	-	4	-	2
N.H.	-	-	-	-	-	-	-	1
Vt.	-	-	1	2	-	2	-	2
Mass.	-	1	-	5	-	20	-	15
R.I.	-	-	-	4	-	-	-	4
Conn.	-	-	-	3	-	1	-	9
MID. ATLANTIC	-	4	11	8	-	37	-	69
Upstate N.Y.	-	1	10	-	-	1	-	25
N.Y. City	-	2	U	U	-	19	-	30
N.J.	-	1	1	6	-	7	-	14
Pa.	-	-	-	2	-	10	-	-
E.N. CENTRAL	1	1	-	-	27	75	3	77
Ohio	1	-	-	-	20	15	-	16
Ind.	-	-	-	-	-	-	-	3
Ill.	-	1	-	-	-	31	-	27
Mich.	-	-	-	-	7	19	3	22
Wis.	-	-	-	-	-	10	-	9
W.N. CENTRAL	-	-	2	11	7	9	1	31
Minn.	-	-	2	1	-	2	-	11
Iowa	-	-	-	-	-	-	-	2
Mo.	-	-	-	-	6	3	1	10
N. Dak.	-	-	-	-	-	-	-	1
S. Dak.	-	-	-	8	-	1	-	2
Nebr.	-	-	-	-	1	3	-	2
Kans.	-	-	-	2	-	-	-	3
S. ATLANTIC	2	4	14	17	25	34	1	106
Del.	-	-	-	1	1	3	-	2
Md.	2	2	4	6	7	11	-	10
D.C.	-	2	-	-	-	1	U	U
Va.	-	-	4	1	-	-	-	17
W. Va.	-	-	-	-	-	-	1	-
N.C.	-	-	6	5	17	16	-	28
S.C.	-	-	-	-	-	-	-	11
Ga.	-	-	-	-	-	1	-	29
Fla.	-	-	-	4	-	2	-	9
E.S. CENTRAL	-	-	-	-	14	11	-	22
Ky.	-	-	-	-	4	6	U	U
Tenn.	-	-	-	-	-	1	-	17
Ala.	-	-	-	-	6	4	-	5
Miss.	-	-	-	-	4	-	-	-
W.S. CENTRAL	-	-	-	-	-	5	-	54
Ark.	-	-	-	-	-	1	-	5
La.	-	-	-	-	-	-	-	12
Okla.	-	-	-	-	-	-	-	1
Tex.	-	-	-	-	-	4	-	36
MOUNTAIN	-	1	2	3	18	17	-	42
Mont.	-	-	1	-	-	1	-	-
Idaho	-	-	-	-	1	-	-	2
Wyo.	-	-	1	1	1	-	-	1
Colo.	-	-	-	-	-	7	-	7
N. Mex.	-	-	-	-	2	1	-	7
Ariz.	-	1	-	2	-	-	-	19
Utah	-	-	-	-	14	2	-	3
Nev.	-	-	-	-	-	6	-	3
PACIFIC	-	8	-	6	-	86	-	124
Wash.	-	-	-	-	-	-	-	9
Oreg.	-	-	-	-	-	4	-	11
Calif.	-	8	-	6	-	69	-	90
Alaska	-	-	-	-	-	1	-	2
Hawaii	-	-	-	-	-	12	-	12
Guam	-	-	-	-	-	2	U	U
P.R.	-	-	-	1	-	2	U	U
V.I.	-	U	-	U	-	U	U	U
Amer. Samoa	-	U	-	U	-	U	U	U
C.N.M.I.	-	U	-	U	-	U	U	U

N: Not notifiable U: Unavailable -: no reported cases

*Individual cases may be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States, weeks ending January 8, 2000, and January 9, 1999 (1st Week)

Reporting Area	Shigellosis*				Syphilis (Primary & Secondary)		Tuberculosis	
	NETSS		PHLIS		Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999†
	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999				
UNITED STATES	39	163	1	174	30	119	4	146
NEW ENGLAND	-	3	-	2	1	2	-	2
Maine	-	-	-	-	-	-	-	-
N.H.	-	-	-	-	-	-	-	-
Vt.	-	-	-	-	-	-	-	-
Mass.	-	3	-	2	1	1	-	-
R.I.	-	-	-	-	-	-	-	-
Conn.	-	-	-	-	-	1	-	2
MID. ATLANTIC	-	10	-	18	-	3	-	-
Upstate N.Y.	-	1	-	4	-	-	-	-
N.Y. City	-	3	-	9	-	3	-	-
N.J.	-	5	-	5	-	-	-	-
Pa.	-	1	-	-	-	-	-	-
E.N. CENTRAL	24	50	-	28	10	15	-	18
Ohio	6	13	-	5	-	3	-	10
Ind.	2	-	-	-	4	2	-	2
Ill.	-	25	-	20	6	7	-	6
Mich.	16	6	-	-	-	-	-	-
Wis.	-	6	-	3	-	3	-	-
W.N. CENTRAL	6	8	-	14	-	3	-	-
Minn.	-	-	-	4	-	-	-	-
Iowa	2	-	-	-	-	-	-	-
Mo.	4	5	-	7	-	3	-	-
N. Dak.	-	-	-	-	-	-	-	-
S. Dak.	-	-	-	-	-	-	-	-
Nebr.	-	3	-	2	-	-	-	-
Kans.	-	-	-	1	-	-	-	-
S. ATLANTIC	1	12	-	11	17	49	-	4
Del.	-	-	-	-	-	-	-	2
Md.	-	3	-	-	3	2	-	-
D.C.	-	1	U	U	-	5	-	-
Va.	-	-	-	-	9	2	-	-
W. Va.	-	-	-	-	-	-	-	1
N.C.	1	2	-	4	5	13	-	-
S.C.	-	-	-	-	-	-	-	-
Ga.	-	-	-	-	-	18	-	-
Fla.	-	6	-	7	-	9	-	1
E.S. CENTRAL	5	4	1	19	-	23	2	7
Ky.	-	2	U	U	-	2	-	1
Tenn.	-	1	1	16	-	13	-	-
Ala.	1	1	-	3	-	7	2	6
Miss.	4	-	-	-	-	1	-	-
W.S. CENTRAL	-	8	-	62	2	18	-	37
Ark.	-	1	-	1	-	1	-	-
La.	-	-	-	3	-	3	-	U
Okla.	-	-	-	-	2	4	-	-
Tex.	-	7	-	58	-	10	-	37
MOUNTAIN	3	5	-	10	-	-	-	1
Mont.	-	-	-	-	-	-	-	-
Idaho	1	1	-	-	-	-	-	-
Wyo.	-	-	-	-	-	-	-	-
Colo.	-	1	-	2	-	-	-	U
N. Mex.	2	2	-	1	-	-	-	-
Ariz.	-	-	-	5	-	-	-	-
Utah	-	1	-	2	-	-	-	-
Nev.	-	-	-	-	-	-	-	1
PACIFIC	-	63	-	10	-	6	2	77
Wash.	-	-	-	6	-	-	2	-
Oreg.	-	-	-	-	-	1	-	1
Calif.	-	59	-	-	-	5	-	71
Alaska	-	-	-	-	-	-	-	1
Hawaii	-	4	-	4	-	-	-	4
Guam	-	1	U	U	-	-	-	-
PR.	-	-	U	U	-	3	-	-
V.I.	-	U	U	U	-	U	-	U
Amer. Samoa	-	U	U	U	-	U	-	U
C.N.M.I.	-	U	U	U	-	U	-	U

N: Not notifiable U: Unavailable -: no reported cases

*Individual cases may be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

†Cumulative reports of provisional tuberculosis cases for 1999 are unavailable ("U") for some areas using the Tuberculosis Information System (TIMS).

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending January 8, 2000, and January 9, 1999 (1st Week)

Reporting Area	<i>H. influenzae</i> , invasive		Hepatitis (Viral), by type				Measles (Rubeola)					
	Cum. 2000†	Cum. 1999	A		B		Indigenous		Imported*		Total	
			Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	2000	Cum. 2000	2000	Cum. 2000	Cum. 2000	Cum. 1999
UNITED STATES	6	23	38	250	26	83	-	-	-	-	-	-
NEW ENGLAND	-	-	-	6	-	4	-	-	-	-	-	-
Maine	-	-	-	1	-	-	-	-	-	-	-	-
N.H.	-	-	-	-	-	-	-	-	-	-	-	-
Vt.	-	-	-	-	-	-	-	-	-	-	-	-
Mass.	-	-	-	4	-	-	-	-	-	-	-	-
R.I.	-	-	-	-	-	-	-	-	-	-	-	-
Conn.	-	-	-	1	-	4	-	-	-	-	-	-
MID. ATLANTIC	1	2	1	13	-	11	-	-	-	-	-	-
Upstate N.Y.	1	-	-	1	-	-	-	-	-	-	-	-
N.Y. City	-	2	1	8	-	3	-	-	-	-	-	-
N.J.	-	-	-	4	-	2	-	-	-	-	-	-
Pa.	-	-	-	-	-	6	-	-	-	-	-	-
E.N. CENTRAL	2	6	18	84	8	9	-	-	-	-	-	-
Ohio	2	2	10	10	2	4	-	-	-	-	-	-
Ind.	-	-	-	-	-	-	-	-	-	-	-	-
Ill.	-	4	-	23	-	-	-	-	-	-	-	-
Mich.	-	-	8	51	6	3	-	-	-	-	-	-
Wis.	-	-	-	-	-	2	-	-	-	-	-	-
W.N. CENTRAL	-	-	12	15	4	7	-	-	-	-	-	-
Minn.	-	-	-	-	-	-	-	-	-	-	-	-
Iowa	-	-	-	-	-	-	-	-	-	-	-	-
Mo.	-	-	12	15	4	4	-	-	-	-	-	-
N. Dak.	-	-	-	-	-	-	U	-	U	-	-	-
S. Dak.	-	-	-	-	-	-	-	-	-	-	-	-
Nebr.	-	-	-	-	-	3	-	-	-	-	-	-
Kans.	-	-	-	-	-	-	-	-	-	-	-	-
S. ATLANTIC	2	8	3	18	14	20	-	-	-	-	-	-
Del.	-	-	-	-	-	-	-	-	-	-	-	-
Md.	2	8	3	9	3	4	-	-	-	-	-	-
D.C.	-	-	-	2	-	-	-	-	-	-	-	-
Va.	-	-	-	-	-	-	-	-	-	-	-	-
W. Va.	-	-	-	-	-	-	-	-	-	-	-	-
N.C.	-	-	-	-	11	16	-	-	-	-	-	-
S.C.	-	-	-	-	-	-	-	-	-	-	-	-
Ga.	-	-	-	7	-	-	-	-	-	-	-	-
Fla.	-	-	-	-	-	-	-	-	-	-	-	-
E.S. CENTRAL	-	-	2	2	-	2	-	-	-	-	-	-
Ky.	-	-	-	-	-	-	-	-	-	-	-	-
Tenn.	-	-	-	-	-	1	-	-	-	-	-	-
Ala.	-	-	1	1	-	1	-	-	-	-	-	-
Miss.	-	-	1	1	-	-	-	-	-	-	-	-
W.S. CENTRAL	-	2	-	10	-	1	-	-	-	-	-	-
Ark.	-	-	-	-	-	1	-	-	-	-	-	-
La.	-	-	-	-	-	-	-	-	-	-	-	-
Okla.	-	1	-	2	-	-	-	-	-	-	-	-
Tex.	-	1	-	8	-	-	-	-	-	-	-	-
MOUNTAIN	1	1	2	21	-	7	-	-	-	-	-	-
Mont.	-	-	-	-	-	-	-	-	-	-	-	-
Idaho	-	-	-	-	-	3	-	-	-	-	-	-
Wyo.	-	1	-	-	-	-	-	-	-	-	-	-
Colo.	-	-	-	9	-	1	-	-	-	-	-	-
N. Mex.	-	-	-	2	-	-	-	-	-	-	-	-
Ariz.	-	-	-	7	-	-	U	-	U	-	-	-
Utah	1	-	2	-	-	-	-	-	-	-	-	-
Nev.	-	-	-	3	-	3	U	-	U	-	-	-
PACIFIC	-	4	-	81	-	22	-	-	-	-	-	-
Wash.	-	-	-	-	-	-	-	-	-	-	-	-
Oreg.	-	1	-	-	-	1	U	-	U	-	-	-
Calif.	-	2	-	81	-	20	-	-	-	-	-	-
Alaska	-	1	-	-	-	1	-	-	-	-	-	-
Hawaii	-	-	-	-	-	-	U	-	U	-	-	-
Guam	-	-	-	-	-	-	U	-	U	-	-	-
P.R.	-	-	-	-	-	-	U	-	U	-	-	-
V.I.	-	U	-	U	-	U	U	-	U	-	-	U
Amer. Samoa	-	U	-	U	-	U	U	-	U	-	-	U
C.N.M.I.	-	U	-	U	-	U	U	-	U	-	-	U

N: Not notifiable U: Unavailable -: no reported cases

*For imported measles, cases include only those resulting from importation from other countries.

†Of 1 case among children aged <5 years, serotype was reported for 0.

TABLE III. (Cont'd.) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending January 8, 2000, and January 9, 1999 (1st Week)

Reporting Area	Meningococcal Disease		Mumps			Pertussis			Rubella		
	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999	2000	Cum. 2000	Cum. 1999
UNITED STATES	15	35	-	-	4	8	8	73	-	-	-
NEW ENGLAND	-	5	-	-	1	-	-	13	-	-	-
Maine	-	2	-	-	-	-	-	-	-	-	-
N.H.	-	-	-	-	-	-	-	-	-	-	-
Vt.	-	-	-	-	-	-	-	1	-	-	-
Mass.	-	3	-	-	1	-	-	12	-	-	-
R.I.	-	-	-	-	-	-	-	-	-	-	-
Conn.	-	-	-	-	-	-	-	-	-	-	-
MID. ATLANTIC	1	2	-	-	-	-	-	1	-	-	-
Upstate N.Y.	-	-	-	-	-	-	-	-	-	-	-
N.Y. City	-	1	-	-	-	-	-	-	-	-	-
N.J.	1	-	-	-	-	-	-	1	-	-	-
Pa.	-	1	-	-	-	-	-	-	-	-	-
E.N. CENTRAL	2	9	-	-	-	-	-	18	-	-	-
Ohio	1	4	-	-	-	-	-	17	-	-	-
Ind.	-	-	-	-	-	-	-	-	-	-	-
Ill.	-	4	-	-	-	-	-	-	-	-	-
Mich.	1	1	-	-	-	-	-	1	-	-	-
Wis.	-	-	-	-	-	-	-	-	-	-	-
W.N. CENTRAL	8	3	-	-	-	-	-	-	-	-	-
Minn.	-	-	-	-	-	-	-	-	-	-	-
Iowa	-	-	-	-	-	-	-	-	-	-	-
Mo.	8	3	-	-	-	-	-	-	-	-	-
N. Dak.	-	-	U	-	-	U	-	-	U	-	-
S. Dak.	-	-	-	-	-	-	-	-	-	-	-
Nebr.	-	-	-	-	-	-	-	-	-	-	-
Kans.	-	-	-	-	-	-	-	-	-	-	-
S. ATLANTIC	3	5	-	-	-	3	3	3	-	-	-
Del.	-	-	-	-	-	-	-	-	-	-	-
Md.	2	3	-	-	-	-	-	3	-	-	-
D.C.	-	-	-	-	-	-	-	-	-	-	-
Va.	-	-	-	-	-	-	-	-	-	-	-
W. Va.	-	-	-	-	-	-	-	-	-	-	-
N.C.	1	1	-	-	-	3	3	-	-	-	-
S.C.	-	1	-	-	-	-	-	-	-	-	-
Ga.	-	-	-	-	-	-	-	-	-	-	-
Fla.	-	-	-	-	-	-	-	-	-	-	-
E.S. CENTRAL	-	1	-	-	-	-	-	3	-	-	-
Ky.	-	-	-	-	-	-	-	-	-	-	-
Tenn.	-	-	-	-	-	-	-	-	-	-	-
Ala.	-	1	-	-	-	-	-	3	-	-	-
Miss.	-	-	-	-	-	-	-	-	-	-	-
W.S. CENTRAL	-	-	-	-	-	-	-	-	-	-	-
Ark.	-	-	-	-	-	-	-	-	-	-	-
La.	-	-	-	-	-	-	-	-	-	-	-
Okla.	-	-	-	-	-	-	-	-	-	-	-
Tex.	-	-	-	-	-	-	-	-	-	-	-
MOUNTAIN	1	5	-	-	-	5	5	22	-	-	-
Mont.	-	-	-	-	-	-	-	-	-	-	-
Idaho	1	1	-	-	-	-	-	9	-	-	-
Wyo.	-	-	-	-	-	-	-	-	-	-	-
Colo.	-	1	-	-	-	-	-	3	-	-	-
N. Mex.	-	1	N	N	N	3	3	2	-	-	-
Ariz.	-	1	U	-	-	U	-	1	U	-	-
Utah	-	-	-	-	-	2	2	6	-	-	-
Nev.	-	1	U	-	-	U	-	1	U	-	-
PACIFIC	-	5	-	-	3	-	-	13	-	-	-
Wash.	-	-	-	-	-	-	-	-	-	-	-
Oreg.	-	3	N	N	N	U	-	-	U	-	-
Calif.	-	1	-	-	1	-	-	13	-	-	-
Alaska	-	1	-	-	-	-	-	-	-	-	-
Hawaii	-	-	U	-	2	U	-	-	U	-	-
Guam	-	-	U	-	-	U	-	-	U	-	-
P.R.	-	-	U	-	-	U	-	-	U	-	-
V.I.	-	U	U	-	U	U	-	U	U	-	U
Amer. Samoa	-	U	U	-	U	U	-	U	U	-	U
C.N.M.I.	-	U	U	-	U	U	-	U	U	-	U

N: Not notifiable U: Unavailable -: no reported cases

TABLE IV. Deaths in 122 U.S. cities,* week ending January 8, 2000 (1st Week)

Reporting Area	All Causes, By Age (Years)						P&J [†] Total	Reporting Area	All Causes, By Age (Years)						P&J [†] Total
	All Ages	≥65	45-64	25-44	1-24	<1			All Ages	≥65	45-64	25-44	1-24	<1	
NEW ENGLAND	705	520	127	39	11	8	76	S. ATLANTIC	1,029	646	223	89	21	43	85
Boston, Mass.	190	118	45	17	7	3	13	Atlanta, Ga.	U	U	U	U	U	U	U
Bridgeport, Conn.	26	17	5	3	-	1	2	Baltimore, Md.	118	67	31	14	2	4	9
Cambridge, Mass.	23	18	5	-	-	-	2	Charlotte, N.C.	143	96	33	11	2	1	15
Fall River, Mass.	23	19	4	-	-	-	2	Jacksonville, Fla.	185	141	32	8	2	2	17
Hartford, Conn.	U	U	U	U	U	U	U	Miami, Fla.	88	54	25	3	2	4	12
Lowell, Mass.	28	19	5	4	-	-	4	Norfolk, Va.	50	28	13	4	3	2	5
Lynn, Mass.	11	10	-	1	-	-	2	Richmond, Va.	61	35	12	6	5	3	4
New Bedford, Mass.	47	38	8	-	-	1	5	Savannah, Ga.	U	U	U	U	U	U	U
New Haven, Conn.	47	33	9	3	1	1	5	St. Petersburg, Fla.	88	61	14	6	3	4	7
Providence, R.I.	83	67	12	2	-	2	5	Tampa, Fla.	179	126	35	16	1	1	14
Somerville, Mass.	7	4	1	1	1	-	-	Washington, D.C.	91	26	23	12	1	22	2
Springfield, Mass.	63	53	6	3	1	-	15	Wilmington, Del.	26	12	5	9	-	-	-
Waterbury, Conn.	47	40	5	2	-	-	5	E.S. CENTRAL	723	523	109	48	22	20	61
Worcester, Mass.	110	84	22	3	1	-	16	Birmingham, Ala.	164	129	15	11	5	3	18
MID. ATLANTIC	2,992	2,172	525	199	48	48	157	Chattanooga, Tenn.	54	37	11	2	3	1	3
Albany, N.Y.	65	48	12	1	3	1	5	Knoxville, Tenn.	65	51	8	3	1	2	7
Allentown, Pa.	U	U	U	U	U	U	U	Lexington, Ky.	40	27	4	5	-	4	1
Buffalo, N.Y.	145	105	25	11	2	2	15	Memphis, Tenn.	127	87	23	10	4	3	4
Camden, N.J.	50	32	10	4	-	4	1	Mobile, Ala.	45	36	7	1	-	1	2
Elizabeth, N.J.	36	24	7	4	1	-	-	Montgomery, Ala.	58	45	8	3	2	-	9
Erie, Pa.	69	58	8	1	2	-	7	Nashville, Tenn.	170	111	33	13	7	6	17
Jersey City, N.J.	89	64	21	2	1	1	-	W.S. CENTRAL	1,616	1,065	352	111	46	42	134
New York City, N.Y.	1,791	1,277	333	132	26	23	59	Austin, Tex.	123	85	21	12	2	3	12
Newark, N.J.	31	10	11	7	2	1	-	Baton Rouge, La.	U	U	U	U	U	U	U
Paterson, N.J.	30	19	5	3	-	3	2	Corpus Christi, Tex.	63	38	19	3	-	3	8
Philadelphia, Pa.	193	141	31	13	2	6	7	Dallas, Tex.	260	147	62	20	17	14	11
Pittsburgh, Pa. [§]	115	90	17	5	-	3	10	El Paso, Tex.	120	95	15	5	2	3	5
Reading, Pa.	37	30	3	1	3	-	4	Ft. Worth, Tex.	162	109	35	11	2	5	21
Rochester, N.Y.	153	123	20	5	2	3	25	Houston, Tex.	350	224	85	25	11	5	19
Schenectady, N.Y.	24	20	3	-	1	-	1	Little Rock, Ark.	62	34	20	6	2	-	6
Scranton, Pa.	37	31	4	2	-	-	5	New Orleans, La.	60	37	14	4	3	2	7
Syracuse, N.Y.	91	70	11	6	3	1	12	San Antonio, Tex.	220	158	42	13	4	3	30
Trenton, N.J.	21	18	1	2	-	-	4	Shreveport, La.	60	43	11	3	2	1	4
Utica, N.Y.	15	12	3	-	-	-	-	Tulsa, Okla.	136	95	28	9	1	3	11
Yonkers, N.Y.	U	U	U	U	U	U	U	MOUNTAIN	1,179	829	223	78	25	23	139
E.N. CENTRAL	2,586	1,820	474	175	50	66	241	Albuquerque, N.M.	154	100	32	18	4	-	20
Akron, Ohio	88	66	11	7	3	1	17	Boise, Idaho	67	45	10	4	2	6	11
Canton, Ohio	59	48	8	3	-	-	3	Colo. Springs, Colo.	51	35	11	4	-	1	3
Chicago, Ill.	292	168	70	35	8	10	26	Denver, Colo.	112	81	19	8	1	2	18
Cincinnati, Ohio	132	98	19	8	2	5	23	Las Vegas, Nev.	221	164	44	9	1	3	16
Cleveland, Ohio	164	108	40	9	2	5	7	Ogden, Utah	30	24	4	-	1	1	6
Columbus, Ohio	269	176	56	21	11	5	25	Phoenix, Ariz.	238	154	50	17	11	6	22
Dayton, Ohio	131	108	16	5	1	1	8	Pueblo, Colo.	40	32	6	2	-	-	5
Detroit, Mich.	328	201	75	31	10	11	25	Salt Lake City, Utah	118	78	27	7	2	4	22
Evansville, Ind.	66	53	9	3	-	1	5	Tucson, Ariz.	148	116	20	9	3	-	16
Fort Wayne, Ind.	65	48	10	6	-	1	3	PACIFIC	1,900	1,420	293	118	45	23	262
Gary, Ind.	29	13	10	4	1	1	4	Berkeley, Calif.	28	20	3	5	-	-	4
Grand Rapids, Mich.	78	53	15	3	1	6	12	Fresno, Calif.	239	170	44	12	12	1	50
Indianapolis, Ind.	212	164	29	7	4	8	18	Glendale, Calif.	20	13	2	5	-	-	-
Lansing, Mich.	59	44	12	3	-	-	4	Honolulu, Hawaii	104	84	15	3	1	1	10
Milwaukee, Wis.	181	144	29	3	1	4	18	Long Beach, Calif.	131	104	13	6	3	5	33
Peoria, Ill.	80	56	16	4	2	2	11	Los Angeles, Calif.	302	204	52	32	8	6	23
Rockford, Ill.	84	66	12	4	-	2	13	Pasadena, Calif.	47	42	3	1	1	-	7
South Bend, Ind.	69	51	9	7	2	-	5	Portland, Oreg.	137	103	22	9	-	2	9
Toledo, Ohio	101	72	20	5	2	2	10	Sacramento, Calif.	U	U	U	U	U	U	U
Youngstown, Ohio	99	83	8	7	-	1	4	San Diego, Calif.	239	188	27	18	6	-	41
W.N. CENTRAL	874	622	150	66	18	18	108	San Francisco, Calif.	U	U	U	U	U	U	U
Des Moines, Iowa	54	45	4	3	1	1	6	San Jose, Calif.	235	182	35	7	6	5	41
Duluth, Minn.	28	25	3	-	-	-	9	Santa Cruz, Calif.	49	38	10	1	-	-	7
Kansas City, Kans.	51	27	15	5	3	1	8	Seattle, Wash.	120	74	31	9	4	2	16
Kansas City, Mo.	87	58	17	9	1	2	3	Spokane, Wash.	93	74	14	1	3	1	8
Lincoln, Nebr.	46	36	5	4	1	-	6	Tacoma, Wash.	156	124	22	9	1	-	13
Minneapolis, Minn.	250	189	35	16	4	6	29	TOTAL	13,604 [¶]	9,617	2,476	923	286	291	1,263
Omaha, Nebr.	74	55	13	4	-	2	9								
St. Louis, Mo.	23	15	5	-	3	-	-								
St. Paul, Minn.	110	84	18	4	1	3	21								
Wichita, Kans.	151	88	35	21	4	3	17								

U: Unavailable - : no reported cases

*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

[†]Pneumonia and influenza.

[§]Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

[¶]Total includes unknown ages.

Errata — Continued

number of hospital discharges (in thousands) for adults aged ≥ 65 years are in parentheses."

Erratum: Vol. 48, No. 43

In the public health achievements report, "Tobacco Use—United States, 1900–1999," the last sentence of the first paragraph on page 989 should read "Total consumption of large cigars decreased from 8 billion in 1970 to 2 billion in 1993 but increased 68% to 3.6 billion in 1997 (13)."

Erratum: Vol. 48, No. 50

In the public health achievements report, "Changes in the Public Health System," the date the Conference (now Council) of State and Territorial Epidemiologists (CSTE) was granted authority to determine what diseases should be reported by states to the Public Health Service was 1951, not 1950 as incorrectly published in the first paragraph on page 1143.

Erratum: Vol. 48, Nos. 51 & 52

In the printed copy and .pdf file of Table 1 of "Abortion Surveillance: Preliminary Analysis—United States, 1997," on pages 1172–3, in the column of data for 1997, "Weeks' gestation," the incorrect numbers of 8.1 and 9.6 for 7 and 8 weeks, respectively, appear. The correct numbers are 18.1 and 19.6, respectively. In the .htm file of Table 1, the ¶ footnote incorrectly stated that the number of reported abortions performed as medical (nonsurgical) was 2983. The correct number is 2988 abortions.

**Contributors to the Production of the *MMWR* (Weekly)
Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data**

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team

Robert Fagan
Jose Aponte
Paul Gangarosa, M.P.H.
Gerald Jones
David Nitschke
Carol A. Worsham

CDC Operations Team

Carol M. Knowles
Deborah A. Adams
Willie J. Anderson
Patsy A. Hall
Kathryn Snavelly
Sara Zywicki

The *Morbidity and Mortality Weekly Report (MMWR) Series* is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/> or from CDC's file transfer protocol server at <ftp.cdc.gov>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control
and Prevention
Jeffrey P. Koplan, M.D., M.P.H.

Acting Deputy Director for Science
and Public Health, Centers for
Disease Control and Prevention
Lynne S. Wilcox, M.D., M.P.H.

Acting Director,
Epidemiology Program Office
Barbara R. Holloway, M.P.H.

Editor, *MMWR* Series
John W. Ward, M.D.

Managing Editor,
MMWR (weekly)
Karen L. Foster, M.A.

Writers-Editors,
MMWR (weekly)
Jill Crane

David C. Johnson
Teresa F. Rutledge
Caran R. Wilbanks

Desktop Publishing
Lynda G. Cupell
Morie M. Higgins